证券代码：688151 证券简称：华强科技 公告编号： 2023-027 湖北华强科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 08 月 31 日(星期四) 下午 14:00-15:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 24 日(星期四) 至 08 月 30 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （office@hqtc.com）进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖北华强科技股份有限 ...

经查明，湖北华强科技股份有限公司（以下简称公司）2022 年 度使用闲置募集资金购买结构性存款获取的投资收益为 2,018.94 万 元。公司于 2023 年 4 月 21 日披露的 2022 年年度报告中，将前述投 资收益认定为经常性损益。2023 年 7 月 18 日，公司披露《关于 2022 年年度报告以及非经常性损益披露差错的补充及更正公告》，将购 买结构性存款获取的投资收益调整认定为非经常性损益,据此对公 司 2022 年年度报告进行更正。其中，2022 年归属于上市公司股东 的扣除非经常性损益的净利润（以下简称扣非归母净利润）由 860.19 万元更正为-855.91 万元，调减金额 1,716.10 万元。 扣非归母净利润是投资者关注的重要指标，可能对公司经营业 绩和盈利能力的判断及投资者决策产生影响。公司结构性存款投资 收益调整认定为非经常性损益，导致公司 2022 年年报扣非归母净利 1 上 海 证 券 交 易 所 上证科创公监函〔2023〕0042 号 关于对湖北华强科技股份有限公司及有关责任 人予以监管警示的决定 当事人： 湖北华强科技股份有限公司，A 股证券简称：华强科技，A 股证 券 ...

Financial Performance - The company reported a net profit attributable to shareholders of RMB 72,433,635.82 for the year 2022, with a cash dividend payout ratio of 36.00%[5]. - The company's operating revenue for 2022 was ¥608.88 million, a decrease of 52.25% compared to ¥1.28 billion in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥72.43 million, down 77.38% from ¥320.22 million in 2021[24]. - The net profit after deducting non-recurring gains and losses was -¥8.56 million, a decline of 103.14% compared to ¥272.72 million in 2021[21]. - The cash flow from operating activities showed a net outflow of -¥181.30 million, a decrease of 138.38% from ¥472.43 million in 2021[24]. - The company's total assets at the end of 2022 were ¥5.17 billion, down 2.37% from ¥5.29 billion at the end of 2021[22]. - The net assets attributable to shareholders decreased slightly to ¥4.19 billion, a reduction of 0.97% from ¥4.23 billion in 2021[22]. - The basic earnings per share for 2022 were ¥0.21, down 83.06% from ¥1.24 in 2021[23]. - The gross profit margin for the main business was 16.61%, a decrease of 26.15 percentage points year-on-year[78]. - The revenue from military products decreased by 49.97% year-on-year due to delays in military procurement orders[80]. Dividend Distribution - As of December 31, 2022, the total distributable profit was RMB 258,899,381.89, with a proposed cash dividend of RMB 0.757 per share (before tax) based on a total share capital of 344,500,000 shares[5]. - The company plans to distribute a total cash dividend of RMB 26,078,650.00 (before tax) to shareholders[5]. - The company maintains a cash dividend policy that requires at least 20% of the distributable profits to be distributed as cash dividends, barring special circumstances[181]. - The company emphasizes a stable and continuous profit distribution policy, balancing investor returns with sustainable development[180]. - The board of directors is responsible for discussing and proposing the profit distribution plan, which must be approved by the shareholders' meeting[181]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 10.79%, up 6.17 percentage points from 4.62% in 2021[23]. - Total R&D investment reached ¥65,709,823.87, an increase of 11.52% compared to the previous year, with R&D expenses accounting for 10.79% of operating revenue, up from 4.62%[59]. - The company has developed 15 core technologies, including integrated design technology for respiratory devices and broad-spectrum protective materials against chemical agents[55]. - The company is committed to continuous R&D investment to maintain its competitive edge in the special protective equipment market, despite facing potential risks from insufficient R&D funding and market competition[75]. - The company is focusing on R&D for new technologies, with an investment of CNY 519,400 allocated to the technology committee[145]. Operational Risks and Governance - The company has outlined various operational risks and corresponding mitigation strategies in the report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[8]. - The company has not disclosed any special arrangements for corporate governance[6]. - The company has established a robust internal control system to enhance risk prevention capabilities and ensure compliance with regulations[137]. Market and Industry Trends - The company faced significant revenue declines due to delays in military equipment orders and a drop in domestic COVID-19 vaccine demand[24]. - The special protection equipment industry is experiencing rapid growth due to increasing defense budgets and the rising demand for advanced military equipment[44]. - The pharmaceutical packaging industry is expected to grow significantly due to rising disposable incomes, an aging population, and expanding health insurance coverage, creating opportunities for upstream pharmaceutical packaging materials[123]. - The competitive landscape in the defense industry is intensifying as the market access threshold for military products has been significantly lowered, allowing more enterprises to enter the sector[121]. Corporate Governance and Management - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and proper governance[135]. - The board of directors has convened seven meetings, maintaining independence and fulfilling its strategic decision-making responsibilities[136]. - The company has established specialized committees under the board, including Audit and Risk Management Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee[167]. - The company has not faced any significant issues regarding independence from its controlling shareholders[138]. - The company has not reported any significant changes in its board of directors or senior management during the reporting period[143]. Environmental and Social Responsibility - The company invested 1.9378 million yuan in environmental protection efforts during the reporting period[192]. - The company disposed of 1,155 tons of general industrial solid waste and 50.26 tons of hazardous waste in compliance with regulations[197]. - The company reduced carbon dioxide equivalent emissions by 418 tons through the implementation of carbon reduction technologies[199]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the upcoming quarter, driven by new product launches and market expansion strategies[146]. - The company plans to pursue strategic acquisitions to enhance its product portfolio and market presence[146]. - New product development is expected to contribute an additional CNY 200 million in revenue over the next fiscal year[146]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of up to 300 million for potential targets[152].

证券代码：688151 证券简称：华强科技 公告编号：2023-017 湖北华强科技股份有限公司 关于参加 2023 年湖北辖区上市公司投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 活动主题：2023 年湖北辖区上市公司投资者网上集体接待日活动 召开时间：2023 年 05 月 25 日(星期四) 14:30-16:35 召开地点：全景路演（http://rs.p5w.net/）网络平台 召开方式：网络文字互动 为进一步加强与广大投资者的互动交流，根据湖北省上市公司协会《关于举 办 2023 年湖北辖区上市公司投资者网上集体接待日活动的通知》，湖北华强科 技股份有限公司（以下简称"公司"）将于 2023 年 5 月 25 日(星期四)14:30-16:35 参加由湖北监管局联合湖北省上市公司协会、深圳市全景网络有限公司举办的 2023 年湖北辖区上市公司投资者网上集体接待日活动，公司将通过网络文字互 动方式与广大投资者沟通交流。现将有关事项公告如下： 一、 活动类型 本次 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥191,850,331.44, representing a decrease of 15.61% compared to the same period last year[4] - The net profit attributable to shareholders was ¥17,123,244.96, down 77.25% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥7,658,581.64, a decline of 84.31% compared to the previous year[4] - The basic and diluted earnings per share were both ¥0.05, down 77.27% from the same period last year[4] - Total operating revenue for Q1 2023 was CNY 191,850,331.44, a decrease of 15.6% compared to CNY 227,344,425.15 in Q1 2022[14] - Net profit for Q1 2023 was CNY 17,123,244.96, down 77.3% from CNY 75,266,226.00 in Q1 2022[15] - Earnings per share for Q1 2023 was CNY 0.05, compared to CNY 0.22 in Q1 2022[16] Cash Flow and Investments - The net cash flow from operating activities was negative at ¥81,949,557.53, a decrease of 21.88% year-on-year[4] - Cash inflow from operating activities totaled CNY 178,577,769.70, an increase from CNY 117,800,599.55 in Q1 2022[17] - The net cash outflow from operating activities was -81,949,557.53, an improvement from -104,908,189.64 in the previous year[18] - Total cash outflow from investment activities amounted to 1,073,089,787.72, significantly higher than 20,465,539.35 in the same period last year[18] - The net cash flow from investment activities was -1,073,089,787.72, compared to -485,539.35 in the previous year[18] - The total cash outflow from financing activities was -87,922.80, indicating minimal financing activity during the quarter[18] - The company reported a decrease in cash and cash equivalents by -1,155,142,168.75 compared to -105,417,820.03 in the previous year[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,125,354,165.36, a decrease of 0.79% from the end of the previous year[5] - As of March 31, 2023, the company's total assets amounted to ¥5,125,354,165.36, a slight decrease from ¥5,166,369,693.67 at the end of 2022[11] - The company's cash and cash equivalents decreased to ¥1,390,354,676.23 from ¥2,545,496,844.98, representing a decline of approximately 45.4%[11] - Total liabilities decreased to CNY 915,274,371.71 from CNY 973,750,671.66 in the previous year[13] - The company's total current liabilities decreased to ¥506,409,488.40 from ¥553,882,993.97, a reduction of approximately 8.6%[12] - The total non-current assets slightly increased to ¥817,647,660.11 from ¥814,727,211.12, showing a growth of about 0.4%[12] - The company reported a decrease in accounts payable to ¥354,575,323.46 from ¥376,040,523.20, a decline of approximately 5.7%[12] Research and Development - The company's R&D investment totaled ¥13,226,047.55, which is 6.89% of operating revenue, down 22.66% year-on-year[5] Shareholder Information - The top two shareholders, China Weaponry Equipment Group and Southern Industrial Asset Management, hold 45.52% and 24.83% of shares, respectively[9] Market and Future Outlook - The company has not reported any new product developments or technological advancements in this quarter[11] - There are no significant market expansion or acquisition strategies mentioned in the report[11] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[11]

Financial Performance - The total distributable profit as of December 31, 2022, was RMB 258,899,381.89, with the parent company's distributable profit at RMB 238,983,608.21[5]. - The proposed cash dividend is RMB 0.757 per share (including tax), amounting to a total of RMB 26,078,650.00 based on a total share capital of 344,500,000 shares[5]. - The net profit attributable to shareholders for the year was RMB 72,433,635.82, with a cash dividend payout ratio of 36.00%[5]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2022 was ¥608,880,588.78, a decrease of 52.25% compared to ¥1,275,242,616.54 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥72,433,635.82, down 77.38% from ¥320,221,815.39 in 2021[24]. - The net profit after deducting non-recurring gains and losses was ¥8,601,873.76, a decline of 96.85% from ¥272,715,928.60 in 2021[21]. - The cash flow from operating activities showed a net outflow of ¥181,302,862.18, a decrease of 138.38% compared to a net inflow of ¥472,426,883.36 in 2021[24]. - The company's total assets at the end of 2022 were ¥5,166,369,693.67, down 2.37% from ¥5,291,914,893.37 at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were ¥4,192,619,022.01, a slight decrease of 0.97% from ¥4,233,697,874.52 at the end of 2021[22]. - Basic earnings per share for 2022 were ¥0.21, down 83.06% from ¥1.24 in 2021[23]. - The company's main business gross margin was 16.61%, a decrease of 26.15 percentage points year-on-year, indicating significant volatility in profitability[86]. - The net cash flow from operating activities was negative CNY 181.30 million, a decline of 138.38% year-on-year, primarily due to delayed sales receipts from military and major customers[82]. Operational Highlights - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The audit report issued by Da Xin Accounting Firm was a standard unqualified opinion[5]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors[7]. - The company experienced a significant decline in sales due to delays in military equipment orders and a drop in demand for vaccine-related products[24]. - The company maintained a 100% contract fulfillment rate for military products, demonstrating strong operational performance[33]. - The company successfully delivered 6 units of a newly developed collective protection system, marking a significant milestone in project development[35]. - Medical device shipments included over 100 million medical masks and 560,000 protective suits, meeting annual targets[34]. - The company completed all 45 reform measures under the state-owned enterprise reform initiative, enhancing operational vitality[34]. - The company’s military and civil products maintained a 100% first-time pass rate during inspections, ensuring quality assurance[33]. Research and Development - The R&D expenditure as a percentage of operating revenue increased by 6.17 percentage points to 10.79% in 2022[23]. - R&D investment reached a historical high as a percentage of revenue, reflecting the company's commitment to technological innovation[35]. - The company has developed 15 core technologies, including integrated design technology for respiratory devices and broad-spectrum filtering materials for military applications[55]. - The company has been recognized as a national high-tech enterprise and has received multiple awards for technological advancements in both military and civilian sectors[55]. - Total R&D investment reached approximately ¥65.71 million, an increase of 11.52% compared to the previous year, with R&D expenses accounting for 10.79% of operating revenue, up from 4.62%[58]. - The number of R&D personnel increased to 139, representing 19.58% of the total workforce, compared to 127 and 17.96% in the previous year[64]. - The company is committed to continuous R&D investment in new technologies and products to maintain its competitive advantage in the special protective equipment market[74]. Market and Industry Trends - The special protection industry is experiencing rapid growth due to increasing defense budgets and the rising demand for advanced military equipment, as outlined in the national "14th Five-Year Plan"[45]. - The global pharmaceutical market is expected to exceed $150 billion by 2025, driven by population growth and aging[47]. - The overall pharmaceutical packaging market in China has a low concentration, with many small enterprises producing simple products, indicating growth opportunities for larger players[47]. - The aging population in China presents significant growth opportunities for the pharmaceutical and pharmaceutical packaging industries[126]. - The implementation of volume-based procurement is driving companies to enhance product quality and develop new products, promoting economies of scale in the pharmaceutical packaging sector[127]. - The competitive landscape in the military supply industry is intensifying, with lower market entry barriers allowing more companies to participate[125]. Corporate Governance and Compliance - The board of directors has approved the profit distribution plan, pending approval at the annual shareholders' meeting[5]. - The company has established a mechanism for independent directors to provide opinions on the profit distribution plan, ensuring transparency and accountability[186]. - The company has established a robust internal control system to enhance risk prevention capabilities and operational standards[141]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate reporting to shareholders through various communication channels[141]. - The company has a structured performance assessment management system for determining senior management remuneration[161]. - The company has established a modern corporate governance structure, including various specialized committees to enhance decision-making efficiency[194]. Environmental and Social Responsibility - The company invested 1.9378 million yuan in environmental protection during the reporting period[195]. - The company consumed 30.2923 million kWh of electricity and 653,200 tons of water in 2022[199]. - The company disposed of 1,155 tons of general industrial solid waste and 50.26 tons of hazardous waste in 2022[200]. - The company reported emissions of 0.0314 tons of sulfur dioxide and 1.43 tons of nitrogen oxides in 2022, all pollutants met discharge standards[200]. - The company emphasizes the integration of ESG into its business strategy to enhance corporate governance and social responsibility[193]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 25% and aiming to reach 1.875 billion[150]. - New product launches are expected to contribute an additional 300 million in revenue in the upcoming year[150]. - Market expansion plans include entering three new international markets by the end of 2023, targeting a 10% market share in each[150]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 500 million allocated for potential deals[150].

证券代码：688151 证券简称：华强科技 公告编号：2023-014 湖北华强科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 28 日(星期五) 上午 10:00-11:30 （一） 会议召开时间：2023 年 04 月 28 日 上午 10:00-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2023 年 04 月 21 日(星期五)至 2023 年 04 月 27 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （office@hqtc.com）进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖北华强科技股份有限公司（以下简称"公司"）已于 202 ...

编号：2022-003 证券代码 688151 证券简称：华强科技 湖北华强科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|---------------------------------------------|---------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关 | □媒体采访 | ☑ 业绩说明会 | | 系活动类 | □新闻发布会 □路演活动 | | | 别 | | □现场参观 □其他（电话沟通） | | 参与单位 | | 通过上海证券交易所上证路演中心和上海证券报·中国证券网参 | | 名称 | 与公司 2021 年度暨 | 2022 年一季度业绩说明会的投资者 | | 时间 | 2022 年 5 月 24 日 | 下午 15:00-16:30 | | 地点 | | 上海证券交易所上证路演中心、上海证券报·中国证券网 | | | 董事长 党委书记：孙光幸先生 | | | | 董事 总经理：高新发先生 | | | 上市公司 | ...

编号：2022-004 证券代码 688151 证券简称：华强科技 湖北华强科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |---------------|-------------------------------|--------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关 | □媒体采访 | ☑ 业绩说明会 | | 系活动类 | □新闻发布会 □路演活动 | | | 别 | □现场参观 | □其他（电话沟通） | | | | 通过全景网"投资者关系互动平台"参与公司" 2022 年湖北辖区 | | 参与单位 名称 | 上市公司投资者集体接待日暨 | 2021 年度业绩说明会"的广大投资 | | | 者 | | | 时间 | 2022 年 6 月 16 日 | 13:00-16:00 | | | 全景网"投资者关系互动平台"（ | http://ir.p5w.net ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥106,011,464.48, a decrease of 73.15% compared to the same period last year[5] - Net profit attributable to shareholders was ¥3,749,603.22, down 96.82% year-on-year[5] - Total operating revenue for Q3 2022 was ¥449,130,915.19, a decrease of 55.6% compared to ¥1,011,001,295.80 in the same period of 2021[34] - Net profit for Q3 2022 was ¥99,449,397.88, a decline of 67.8% compared to ¥308,956,966.44 in Q3 2021[36] - Basic earnings per share for Q3 2022 were ¥0.29, down from ¥1.20 in the same quarter of 2021[39] Cash Flow - The cash flow from operating activities showed a net outflow of ¥35,826,635.82, a decrease of 65.63% compared to the previous year[5] - Operating cash flow net amount was -$166.13 million, a decrease from -$43.16 million year-over-year[43] - Total cash inflow from operating activities was $407.12 million, down from $811.65 million year-over-year[43] - Cash outflow from operating activities totaled $573.25 million, compared to $854.82 million in the previous year[43] - The ending cash and cash equivalents balance was $3.32 billion, down from $476.13 million at the beginning of the period[44] Research and Development - Research and development expenses totaled ¥13,553,094.74, representing 12.78% of operating revenue, an increase of 9.06 percentage points year-on-year[7] - The company increased its R&D investment by 35.04% year-on-year, actively engaging in research activities[15] - Research and development expenses for Q3 2022 were ¥48,255,016.85, an increase of 35.0% compared to ¥35,734,029.80 in Q3 2021[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,122,829,349.15, a decrease of 3.20% from the end of the previous year[7] - The company's current assets totaled approximately ¥4.33 billion, down from ¥4.50 billion, indicating a decrease of around 3.7%[28] - Total liabilities as of the end of the reporting period were ¥903,218,971.83, down 14.7% from ¥1,058,217,018.85 at the end of the previous period[34] - The company's short-term liabilities included accounts payable of approximately ¥357.24 million, up from ¥328.45 million, an increase of about 8.8%[28] - The company’s non-current assets totaled approximately ¥791.07 million, slightly down from ¥793.62 million, a decrease of about 0.3%[28] Operational Challenges - The company experienced a significant decline in operating income due to delayed deliveries of special protective equipment orders and a slowdown in revenue contribution from vaccine rubber plugs[15] - Total operating costs for Q3 2022 were ¥409,534,735.71, down 38.4% from ¥665,281,924.21 year-over-year[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,629[17] - Total equity attributable to shareholders was ¥4,219,610,377.32, a slight decrease from ¥4,233,697,874.52 in the previous period[34] Financial Expenses - Financial expenses for Q3 2022 were -¥44,193,280.28, compared to -¥11,159,358.76 in Q3 2021, indicating a significant increase in financial costs[34]